Clinical Trials Logo

Clinical Trial Summary

The primary objectives are to evaluate the safety and tolerability of multiple doses of ION464 administered via intrathecal (IT) injection (Part 1) and to evaluate the long-term safety and tolerability of ION464 (Part 2) in participants with multiple system atrophy (MSA). The secondary objectives are to evaluate the pharmacodynamic (PD) effect of ION464 on the level of a potential biomarker of target engagement (Parts 1 and 2) and to evaluate the pharmacokinetic (PK) profile of ION464 in serum (Part 1).


Clinical Trial Description

This is a first-in-human, randomized, blinded, placebo-controlled, multiple-ascending-dose (MAD) study (Part 1) to evaluate the safety, tolerability, PK, and PD of ION464 in adult participants diagnosed with MSA with a long-term extension (LTE) (Part 2). The study will include up to approximately 40 participants. Part 1 of the study consists of a Screening Period of up to 6 weeks, a Treatment Period of 12 weeks, and a Follow-up Period of 24 weeks. The study duration for each participant in Part 2 will be approximately 96 weeks, which consists of a 72-week Treatment Period and a 24-week Follow-up Period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04165486
Study type Interventional
Source Ionis Pharmaceuticals, Inc.
Contact Ionis Pharmaceuticals, Inc.
Phone (844) 748-5844
Email IonisHORIZONStudy@clinicaltrialmedia.com
Status Recruiting
Phase Phase 1
Start date July 21, 2022
Completion date September 2027

See also
  Status Clinical Trial Phase
Completed NCT03593512 - Deep Brain Stimulation for Autonomic and Gait Symptoms in Multiple System Atrophy N/A
Recruiting NCT03648905 - Clinical Laboratory Evaluation of Chronic Autonomic Failure
Active, not recruiting NCT05699460 - Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
Recruiting NCT02897063 - Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Phase 1
Not yet recruiting NCT00758849 - Fipamezole in Neurogenic Orthostatic Hypotension Phase 2
Completed NCT01155492 - Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease N/A
Recruiting NCT04431713 - Exenatide Once-weekly as a Treatment for Multiple System Atrophy Phase 2
Completed NCT04184063 - Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) Phase 2
Recruiting NCT05121012 - Synaptic Loss in Multiple System Atrophy
Terminated NCT03589976 - A Futility Trial of Sirolimus in Multiple System Atrophy Phase 2
Recruiting NCT04706234 - Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies
Completed NCT00368199 - Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes N/A
Recruiting NCT04472130 - Neurodegenerative Diseases Registry
Recruiting NCT04876326 - Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy N/A
Recruiting NCT04680065 - GDNF Gene Therapy for Multiple System Atrophy Phase 1
Completed NCT03753763 - Safinamide for Multiple System Atrophy (MSA) Phase 2
Recruiting NCT04250493 - Insulin Resistance in Multiple System Atrophy N/A
Recruiting NCT06072105 - Medical Decision Making in Multiple System Atrophy N/A
Terminated NCT02149901 - Water and Sudafed in Autonomic Failure Early Phase 1
Terminated NCT00997672 - Lithium in Multiple System Atrophy Phase 2